単純ヘルペス感染症(Herpes Simplex Infections)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Herpes Simplex Infections Overview 9
Therapeutics Development 10
Pipeline Products for Herpes Simplex Infections – Overview 10
Pipeline Products for Herpes Simplex Infections – Comparative Analysis 11
Herpes Simplex Infections – Therapeutics under Development by Companies 12
Herpes Simplex Infections – Therapeutics under Investigation by Universities/Institutes 16
Herpes Simplex Infections – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Herpes Simplex Infections – Products under Development by Companies 20
Herpes Simplex Infections – Products under Investigation by Universities/Institutes 24
Herpes Simplex Infections – Companies Involved in Therapeutics Development 25
3-V Biosciences, Inc. 25
Adamis Pharmaceuticals Corporation 26
Admedus Ltd 27
Agenus, Inc. 28
AiCuris GmbH & Co. KG 29
AlphaVax, Inc. 30
Astellas Pharma Inc. 31
Beech Tree Labs, Inc. 32
BioApex, s.r.o. 33
CEL-SCI Corporation 34
Chimerix, Inc. 35
Colby Pharmaceutical Company 36
Epiphany Biosciences, Inc. 37
Foamix Pharmaceuticals Ltd. 38
Genocea Biosciences, Inc. 39
GenVec, Inc. 40
Immune Design Corp. 41
Immunovaccine, Inc. 42
Kala Pharmaceuticals, Inc. 43
Mymetics Corporation 44
NanoBio Corporation 45
NanoViricides, Inc. 46
NovaBay Pharmaceuticals, Inc. 47
Onxeo SA 48
Oryzon Genomics S.A. 49
Osel Inc. 50
PaxVax 51
Peregrine Pharmaceuticals, Inc. 52
Profectus BioSciences, Inc. 53
Romark Laboratories, L.C. 54
Sanofi 55
Sanofi Pasteur SA 56
Spider Biotech 57
Starpharma Holdings Limited 58
Vaccibody AS 59
Vaxart, Inc. 60
Vical Incorporated 61
Vironova AB 62
ViroStatics, srl 63
Herpes Simplex Infections – Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Target 66
Assessment by Mechanism of Action 68
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(celecoxib + famciclovir) – Drug Profile 74
acyclovir – Drug Profile 75
acyclovir – Drug Profile 76
acyclovir – Drug Profile 77
amenamevir – Drug Profile 78
Aspidasept – Drug Profile 79
astodrimer – Drug Profile 80
BA-368 – Drug Profile 82
Biologic for Infectious Disease – Drug Profile 83
brincidofovir – Drug Profile 84
BTL-TMLHSV – Drug Profile 86
C-31G – Drug Profile 87
CEL-1000 – Drug Profile 89
G-103 – Drug Profile 91
GEN-002 – Drug Profile 92
GEN-003 – Drug Profile 93
genital herpes vaccine – Drug Profile 95
genital herpes vaccine [HSV-2] – Drug Profile 96
GV-2207 – Drug Profile 97
HerpeCide-I – Drug Profile 98
herpes [Type-2] vaccine – Drug Profile 99
herpes simplex [HSV-2] vaccine – Drug Profile 100
herpes simplex vaccine – Drug Profile 101
herpes simplex vaccine – Drug Profile 102
herpes simplex virus [type 1, 2] vaccine – Drug Profile 103
herpes simplex virus [type 1] vaccine – Drug Profile 104
herpes simplex virus vaccine – Drug Profile 105
herpes simplex virus vaccine – Drug Profile 106
herpes simplex virus vaccine – Drug Profile 107
herpes simplex virus vaccine – Drug Profile 108
herpes simplex virus vaccine – Drug Profile 109
HSV [type 2] vaccine – Drug Profile 110
HSV vaccine – Drug Profile 111
HSV-529 – Drug Profile 112
JVRS-100 + herpes simplex virus-2 vaccine – Drug Profile 114
Labyrinthopeptine A1 – Drug Profile 115
MB-66 – Drug Profile 116
Monoclonal Antibodies for HIV and Herpes Simplex Infections – Drug Profile 117
Monoclonal Antibody for Herpes Simplex Infections – Drug Profile 118
Monoclonal Antibody for Herpes Simplex Infections – Drug Profile 119
NVC-638 – Drug Profile 120
NVC-704 – Drug Profile 121
NVC-727 – Drug Profile 122
PGN-632 – Drug Profile 123
pritelivir – Drug Profile 124
RC-100b – Drug Profile 125
RKP-00156 – Drug Profile 126
SB-105 – Drug Profile 127
SB105-A10 – Drug Profile 128
Small Molecule to Inhibit CDK9 for EBV and HSV Infections – Drug Profile 130
Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections – Drug Profile 131
Small Molecule to Inhibit LSD-1 for HSV – Drug Profile 132
Small Molecules for Bacterial and Viral Infections – Drug Profile 133
Small Molecules for Herpes Simplex and Hepatitis C Infections – Drug Profile 134
Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections – Drug Profile 135
Small Molecules for Viral Infections – Drug Profile 136
Synthetic Peptide for Oncology and Infectious Disease – Drug Profile 137
Synthetic Peptides for Influenza, HSV and HIV Infections – Drug Profile 138
Synthetic Peptides for Viral Infections – Drug Profile 139
UB-621 – Drug Profile 140
valomaciclovir stearate – Drug Profile 141
VCLHB-01 – Drug Profile 143
VCLHM-01 – Drug Profile 144
VN-180 – Drug Profile 145
Herpes Simplex Infections – Recent Pipeline Updates 146
Herpes Simplex Infections – Dormant Projects 170
Herpes Simplex Infections – Discontinued Products 174
Herpes Simplex Infections – Product Development Milestones 175
Featured News & Press Releases 175
Appendix 183
Methodology 183
Coverage 183
Secondary Research 183
Primary Research 183
Expert Panel Validation 183
Contact Us 183
Disclaimer 184